Page 3 - Drug Makers In India

Lupin recieves USFDA nod to market generic anthelmintic tablets

According to IQVIA MAT April 2020 data, Albendazole tablets had an annual sales of around $34 million in the US, Lupin said

Joint inflammation drug may be repurposed to treat Covid-19: EMBO Study

According to the study, baricitinib also helped reduce the quantity of the novel coronavirus in infected cells

Hyderabad's Raghav Life Sciences develops Favipiravir for Covid-19 patients

Firm says it has been in talks with at least eight buyers, including a few overseas companies, to supply the anti-retroviral drug

Strong Q4 performance, debt reduction show Aurobindo Pharma in good health

Despite an over 150 per cent rise since March lows, the stock can see more gains

FDA new drug approval run rate down in FY20 for most Indian pharma majors

According to analysts, companies are skeptical about entering crowded opportunities

Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business

The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period

Covid-19 lockdown: After April shock, drug sales improve in May

Till May 15, the overall inventory was 39 days, compared to 43 days in first half of the previous month

Coronavirus outbreak: India plans ayurvedic trials on patients soon

On the preventive front, many states, including Haryana, Goa and Kerala, have started using ayurvedic medicines for asymptomatic patients and even frontline workers.

India's only quinine making unit set up in 1874, has been shut since 2001

Covid-19 has triggered a sense of urgency to revive this sick unit, as Hydroxychloroquine, an anti-malarial drug, surfaced as potential medicine to alleviate the symptoms of the disease

Govt moves to check over-the-counter selling of coronavirus drugs

Sensing serious health risks, the government has swung into action. Dispensing of these medicines would get stricter and states have started collecting information on available stock in the market

Ample drug ingredients for next 3 months; monitoring situation, says Govt

All initiatives are being taken to ensure there is no impact of the disease in India, Minister of Chemicals and Fertilizers D V Sadananda Gowda said

Govt sanctions Rs 1,850 cr to ensure better drug monitoring systems

A significant share of this money will go into upgrading the Sugam portal - the e-governance solution for CDSCO.

Coronavirus impact: Icra downgrades domestic pharma outlook to negative

According to Icra research, domestic API manufacturers have an inventory of one-two months

In a booster dose, pharma industry gets 'green' signal in New Year

Drug makers allowed to tweak product mix or quantity without fresh environment clearance until effluent load is same

Drug controller cracks whip on e-pharmacies selling drugs without licences

Last December the Delhi High Court had said online sale of medicines without a licence was injuncted, and had instructed the government to ensure that the same was prohibited forthwith

Indian pharmaceutical companies spread business to avoid regulatory ire

Increased USFDA import alerts could be reason for finding alternative sites

The antibiotics challenge

Don't extend price caps on drugs

Domestic drug portfolio a key driver of Ajanta Pharma's growth prospects

Industry beating growth along with high US sales are keeping analysts positive on the company's earnings prospects

Drug marketers to be held liable for quality churned out by third parties

Onus of quality and labelling is currently with drug maker, marketers just need licence to sell. Rule change will make marketers more accountable, greater scrutiny may boost quality, say experts